Harrow, Inc. (NASDAQ:HROW) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Harrow, Inc. (NASDAQ:HROW) have been assigned an average rating of “Moderate Buy” from the eleven brokerages that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $69.8571.

HROW has been the subject of a number of research analyst reports. Nomura cut Harrow to a “neutral” rating in a report on Wednesday, March 18th. Weiss Ratings restated a “sell (e+)” rating on shares of Harrow in a report on Thursday, January 22nd. BTIG Research restated a “buy” rating and set a $63.00 target price on shares of Harrow in a report on Wednesday, March 18th. Zacks Research upgraded Harrow from a “strong sell” rating to a “hold” rating in a report on Friday, April 3rd. Finally, William Blair restated an “outperform” rating on shares of Harrow in a report on Tuesday, March 3rd.

Harrow Stock Performance

NASDAQ HROW opened at $35.43 on Wednesday. The stock has a fifty day simple moving average of $41.75 and a 200-day simple moving average of $43.05. Harrow has a twelve month low of $20.85 and a twelve month high of $54.85. The stock has a market cap of $1.32 billion, a PE ratio of -208.40 and a beta of 0.31. The company has a current ratio of 2.20, a quick ratio of 2.06 and a debt-to-equity ratio of 4.67.

Hedge Funds Weigh In On Harrow

A number of hedge funds and other institutional investors have recently bought and sold shares of HROW. Royal Bank of Canada boosted its holdings in Harrow by 102.5% during the 1st quarter. Royal Bank of Canada now owns 9,813 shares of the company’s stock valued at $261,000 after acquiring an additional 4,967 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Harrow by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 18,146 shares of the company’s stock valued at $483,000 after acquiring an additional 790 shares during the period. Strs Ohio purchased a new position in Harrow during the 1st quarter valued at about $149,000. Legal & General Group Plc boosted its stake in shares of Harrow by 12.4% in the 2nd quarter. Legal & General Group Plc now owns 30,753 shares of the company’s stock valued at $939,000 after buying an additional 3,384 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Harrow by 9.3% in the 2nd quarter. Rhumbline Advisers now owns 46,969 shares of the company’s stock valued at $1,434,000 after buying an additional 3,994 shares during the period. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.